'tAnGo', A Phase III Randomised Trial Of Gemcitabine In Paclitaxel-Containing, Epirubicin-Based, Adjuvant Chemotherapy For ER/PgR-Poor, Early Stage, Breast Cancer

Trial Profile

'tAnGo', A Phase III Randomised Trial Of Gemcitabine In Paclitaxel-Containing, Epirubicin-Based, Adjuvant Chemotherapy For ER/PgR-Poor, Early Stage, Breast Cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 19 May 2017

At a glance

  • Drugs Gemcitabine (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Breast cancer; Early breast cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms tAnGo
  • Most Recent Events

    • 10 May 2017 Status changed from active, no longer recruiting to completed.
    • 28 Feb 2012 Company added as trial sponsor and additional lead trial investigator identified as reported by UKCRN.
    • 07 Apr 2009 Additional lead trial investigator Christopher Poole identified as reported by United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top